FibroGen/$FGEN
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About FibroGen
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
Ticker
$FGEN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
225
ISIN
US31572Q8814
Website
FibroGen Metrics
BasicAdvanced
$21M
-
-$2.49
0.82
-
Price and volume
Market cap
$21M
Beta
0.82
52-week high
$6.02
52-week low
$5.16
Financial strength
Current ratio
2.024
Quick ratio
0.46
Long term debt to equity
-52.146
Total debt to equity
-52.146
Interest coverage (TTM)
-11.48%
Profitability
EBITDA (TTM)
-94.375
Gross margin (TTM)
-798.34%
Net profit margin (TTM)
-143.04%
Operating margin (TTM)
-1,380.42%
Effective tax rate (TTM)
0.23%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-22.73%
Return on equity (TTM)
66.92%
Valuation
Price to revenue (TTM)
2.966
Price to book
-0.1
Price to tangible book (TTM)
-0.1
Price to free cash flow (TTM)
-0.272
Free cash flow yield (TTM)
-367.44%
Free cash flow per share (TTM)
-1,895.94%
Growth
Revenue change (TTM)
-80.57%
Earnings per share change (TTM)
-95.93%
3-year revenue growth (CAGR)
-69.95%
10-year revenue growth (CAGR)
-25.68%
3-year earnings per share growth (CAGR)
-68.00%
10-year earnings per share growth (CAGR)
-29.38%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for FibroGen stock?
FibroGen (FGEN) has a market cap of $21M as of June 20, 2025.
What is the P/E ratio for FibroGen stock?
The price to earnings (P/E) ratio for FibroGen (FGEN) stock is 0 as of June 20, 2025.
Does FibroGen stock pay dividends?
No, FibroGen (FGEN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next FibroGen dividend payment date?
FibroGen (FGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for FibroGen?
FibroGen (FGEN) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.